Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Benchmark International Facilitated the trans btwn Poly Pharmaceuticals, Inc. and ADDvise Group, ABThe buyer, ADDvise Group, AB, is a leading global supplier to healthcare and research facilities. The group's subsidiaries are organized into two business areas: Lab and Healthcare. ADDvise shares are listed on Nasdaq First North Premier. "The Mangold team (representing ADDvise) is very pleased with the cooperation with Benchmark International in the implementation of this transaction. Their team has been very professional, helpful, and efficient throughout the process. We look forward to continuing the work with Benchmark International in the future with new transactions." "Poly Pharm was an extremely attractive business that made a name for themselves in the fragmented OTC pharmaceutical space. The ADDvise group realized what Poly Pharm accomplished and was excited to continue their legacy. It was a pleasure working alongside two great companies." – Matthew Kekelis, Director, Benchmark International Americas: Sam Smoot at +1 (813) 898 2350 / Smoot@BenchmarkIntl.com Europe: Michael Lawrie at +44 (0) 161 359 4400 / Enquiries@BenchmarkIntl.com Africa: Anthony McCardle at +27 21 300 2055 / McCardle@BenchmarkIntl.com ABOUT BENCHMARK INTERNATIONAL Benchmark International's global offices provide business owners in the middle market and lower middle market with creative, value-maximizing solutions for growing and exiting their businesses. To date, Benchmark International has handled engagements in excess of $8.25B across various industries worldwide. With decades of global M&A experience, Benchmark International's deal teams, working from 14 offices across the world, have assisted thousands of owners with achieving their personal objectives and ensuring the continued growth of their businesses. Website: http://www.benchmarkintl.com Blog: http://blog.benchmarkcorporate.com End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|